CRISPR Therapeutics AG (CRSP)
40.72
+0.34
(+0.83%)
USD |
NASDAQ |
Dec 20, 16:00
40.87
+0.15
(+0.37%)
After-Hours: 20:00
CRISPR Therapeutics Enterprise Value: 1.540B for Dec. 20, 2024
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Vertex Pharmaceuticals Inc | 95.78B |
| Lonza Group Ltd | 44.84B |
| AC Immune SA | 77.48M |
| Addex Therapeutics Ltd | 4.458M |
| NLS Pharmaceutics Ltd | 8.486M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -85.94M |
| Total Expenses (Quarterly) | 110.13M |
| EPS Diluted (Quarterly) | -1.01 |
| Earnings Yield | -6.88% |
| Normalized Earnings Yield | -4.740 |